Alumis Inc. Common Stock (ALMS) Financial Analysis & Valuation | Quarter Chart
Company facts
Reported company information and share structure.
| Market Cap | $980.05M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Martin Babler |
| IPO Date | 2024-06-28 | CAGR | — |
| Employees | 237 | Website | www.alumis.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
Key metrics
Reported fundamentals and market-derived technical indicators.
| EV | $1.53B | P/E | -2.03 | Forward P/E | -2.92 | PEG | — |
| P/S | 0.01 | P/B | — | P/CF | — | P/FCF | — |
| Sales | $7.40M | Sales 1Y | -63.11% | Sales 3Y | — | Sales 5Y | — |
| EPS | $-3.92 | EPS 1Y | -15.93% | EPS 3Y | — | EPS 5Y | — |
| Sales QoQ | -4.54% | EPS QoQ | 50% | Sales QoQ Avg | -10.86% | EPS QoQ Avg | -55.14% |
| Gross Margin | 65.76% | Operating Margin | -6204.39% | Profit Margin | -5933.45% | ROCE | -94.76% |
| ROA | -78% | ROE | -103% | Altman Z Score | 0.91 | Piotroski Score | 2 |
| Current Ratio | 6.74 | Quick Ratio | 6.74 | Cash Ratio | 0.84 | Op. CF Ratio | -1.07 |
| Debt/Equity | 0.08 | Debt/Assets | 0.06 | Lt Debt/Equity | 0.07 | Lt Debt/Cap. | 0.07 |
| Intrst Cov. | — | Inventory Turnover | — | Asset Turnover | 0.01 | Receivables Turnover | — |
| Enterprise Value | $1.53B | P/E Ratio | -2.03 |
| Forward P/E | -2.92 | PEG Ratio | — |
| P/S Ratio | 0.01 | P/B Ratio | — |
| P/CF Ratio | — | P/FCF Ratio | — |
| EPS | $-3.92 | EPS Growth 1Y | -15.93% |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | -63.11% | Gross Margin | 0.66% |
| Operating Margin | -62.04% | Profit Margin | -59.33% |
| ROE | -1.03% | ROA | -0.78% |
| ROCE | -0.95% | Current Ratio | 6.74 |
| Quick Ratio | 6.74 | Cash Ratio | 0.84 |
| Debt/Equity | 0.08 | Interest Coverage | — |
| Altman Z Score | 0.91 | Piotroski Score | 2 |
Alumis Inc. Common Stock (ALMS) valuation & financials
Alumis Inc. Common Stock (ALMS) has a market capitalization of $980.05M and trades at a price-to-earnings ratio of -2.0. It operates in the Healthcare sector (Biotechnology).
Alumis Inc. Common Stock's revenue grew -63.1% over the last year.
Alumis Inc. Common Stock's next earnings report is scheduled for November 12, 2026 after market close; analysts estimate EPS of $-0.73. Check the earnings calendar to see all companies reporting this week.
Alumis Inc. Common Stock (ALMS) — frequently asked questions
When does Alumis Inc. Common Stock (ALMS) report earnings next?
Alumis Inc. Common Stock is expected to report earnings on November 12, 2026 after market close. Analysts estimate EPS of $-0.73.
What is Alumis Inc. Common Stock's market cap?
Alumis Inc. Common Stock (ALMS) has a market capitalization of $980.05M.
What is ALMS's P/E ratio?
Alumis Inc. Common Stock trades at a price-to-earnings ratio of -2.0, with trailing twelve-month EPS of $-3.92.
How fast is Alumis Inc. Common Stock growing?
Alumis Inc. Common Stock's revenue grew -63.1% over the last year.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · Merck (MRK) · UnitedHealth (UNH) · Roche (ROG.SW)